CD274 and neoplasm: Indeed, in an analytical study comparing three PD-L1 assays in TNBC tumor samples from the phase III IMpassion130 clinical trial, PD-L1 positivity with the clone SP263 was 74.9% using a threshold ≥1% of the tumor area and peri-tumoral stroma only occupied by PD-L1-positive immune cells21.